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Abstract
Alzheimer’s disease (AD) is pathologically characterized by the accumulation of amyloid-β (Aβ) plaques,
neurofibrillary tangles and widespread neuronal loss in the brain. In recent years, blood biomarkers have emerged
as a realistic prospect to highlight accumulating pathology for secondary prevention trials. Neurofilament light
chain (NfL), a marker of axonal degeneration, is robustly elevated in the blood of many neurological and
neurodegenerative conditions, including AD. A strong relationship with cerebrospinal fluid (CSF) NfL suggests that
these biomarker modalities reflect the same pathological process. Yet, the connection between blood NfL and brain
tissue pathology has not been directly compared. In this study, longitudinal plasma NfL from cognitively healthy
controls (n = 12) and AD participants (n = 57) were quantified by the Simoa platform. On reaching post-mortem,
neuropathological assessment was performed on all participants, with additional frozen and paraffin-embedded
tissue acquired from 26 participants for further biochemical (Aβ1–42, Aβ1–40, tau) and histological (NfL) evaluation.
Plasma NfL concentrations were significantly increased in AD and correlated with cognitive decline, independent of
age. Retrospective stratification based on Braak staging revealed that baseline plasma NfL concentrations were
associated with higher neurofibrillary tangle pathology at post-mortem. Longitudinal increases in plasma NfL were
observed in all Braak groupings; a significant negative association, however, was found between plasma NfL at time
point 1 and both its rate of change and annual percentage increase. Immunohistochemical evaluation of NfL in the
medial temporal gyrus (MTG) demonstrated an inverse relationship between Braak stages and NfL staining.
Importantly, a significant negative correlation was found between the plasma NfL measurement closest to death
and the level of NfL staining in the MTG at post-mortem. For the first time, we demonstrate that plasma NfL
associates with the severity of neurofibrillary tangle pathology and neurodegeneration in the post-mortem brain.
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Introduction
In recent years, there has been an increasing emphasis
on developing a blood biomarker (plasma or serum) to
predict the clinical onset of Alzheimer’s disease (AD) or
to identify the underlying pathophysiology at its earliest
stage. A blood-based measure has substantial practical
and economic advantages over the most well-established
AD biomarkers. Structural imaging (MRI) and positron
emission tomography (PET) techniques using 18F-fluoro-
deoxyglucose, amyloid tracers, and, more recently, tau
ligands are costly, and access is limited to specialised
centres. On the other hand, cerebrospinal fluid (CSF)
sampling is becoming routine in neurology clinics and
the cost for the core AD CSF immunological assays
(Aβ1–42, phosphorylated tau [P-tau] and total tau
[T-tau]) are much lower per patient than for PET scans.
Yet, there remains a level of perceived invasiveness or
complexity attached to a lumbar puncture in many
countries. Therefore, a blood-based marker would com-
plement CSF and molecular imaging biomarkers as a
simplified initial triage step in a multi-stage assessment
for early diagnosis, secondary prevention trial participant
selection or monitoring of response to intervention over
time (for review see, (Lewczuk et al. 2017)).
It has proven challenging to establish a robust blood
biomarker for AD. Candidate proteins are influenced by
peripheral expression from extra-cerebral tissues and the
measurements are confounded by matrix effects from
plasma proteins (Zetterberg 2015). More recently, ultra-
sensitive immunological assays (Single Molecule Array)
and mass spectrometric studies have overcome these
complications and recently reported plasma amyloid-beta
peptide ratios (Aβ1–42/Aβ1–40 and APP699–711/Aβ1–42) that
can identify cerebral amyloidosis with high accuracy (Jane-
lidze et al. 2016; Nakamura et al. 2018). Furthermore,
using the Simoa platform, plasma T-tau has been shown
to be consistently elevated in AD (Mattsson et al. 2016)
and to correlate with cognitive decline (Mielke et al.
2017). However, there are large overlaps in concentrations
between clinical groups, with a poor association with CSF
T-tau (Mattsson et al. 2016; Zetterberg et al. 2013). One
promising avenue for AD is the neuroaxonal injury
marker neurofilament light (NfL). Patients with AD have
increased NfL concentrations in the CSF (Sjogren et al.
2000) and this is also reflected in the blood despite being
more than 50-fold lower in concentration (Gisslen et al.
2016; Lewczuk et al. 2018). Increases in blood NfL have
also been described in frontotemporal dementia (Rohrer
et al. 2016), Huntington’s disease (Byrne et al. 2017) and
atypical parkinsonian disorders (Hansson et al. 2017),
making blood NfL a global marker of neurodegeneration
rather than a disease-specific biomarker per se. Intri-
guingly, plasma NfL correlates highly with CSF NfL in the
same individuals (correlation coefficients > 0.75 (Zetterberg
and Blennow 2018)), further supporting the notion that
plasma NfL indeed reflects central nervous system damage
and could be used as a proxy measure for CSF NfL. How-
ever, at this time, no evidence has been gathered to suggest
if blood NfL reflects the degree of neuropathology at
post-mortem.
In this study, we sought to investigate this relationship
by measuring longitudinal plasma NfL concentrations in
cognitively unimpaired elderly controls (CTL) and pa-
tients with a clinical diagnosis of probable AD. For all
participants, Braak staging of tau pathology was per-
formed at post-mortem. Biochemical measures of brain
Aβ (Aβ1–42, Aβ1–40 and Aβ1–42/ Aβ1–40) and tau (P-tau
and T-tau), as well as immunohistochemical assessment
of NfL, were performed in a subset.
Materials and methods
Study participants
The current study is comprised of two cohorts; the Alz-
heimer Research Trust (ART) cohort and the dementia
case register (DCR). The details regarding the process of
recruitment and clinical diagnosis have been previously
described (Hye et al. 2006, 2014). In brief, the diagnosis
of probable AD was made according to Diagnostic and
Statistical Manual for Mental Diagnosis, fourth edition
and National Institute of Neurological, Communicative
Disorders and Stroke–Alzheimer’s disease and Related
Disorders Association (NINCDS-ADRDA) clinical cri-
teria. Standardized clinical assessments included the
informant interview for diagnosis and the Mini-Mental
State Examination (MMSE). CTL subjects were either
spouses of cases or recruited though primary care age-
sex registers; all had MMSE > 26. The APOE single
nucleotide polymorphisms (SNPs) rs429358 and rs7412
were genotyped using Taqman SNP genotyping assays
(determined by allelic discrimination assays based on
fluorogenic 5′ nuclease activity) and the allele inferred.
The human biological samples were sourced ethically,
and their research use was in accordance with the terms
of the informed consent. To be included in the present
study, participants must have completed one or more
blood draws throughout life and have reached post-mor-
tem with a pathological assessment at the MRC London
Neurodegenerative Diseases Brain Bank. We included 72
participants meeting such criteria (Table 1). Consent for
autopsy, neuropathological assessment and research was
obtained for all cases and the study was carried out
under the ethical approval of the tissue bank. Block taking
and neuropathological assessment was performed accord-
ing to standard criteria (for more detail see (Skogseth
et al. 2017)). This included assessment for vascular lesions,
TAR DNA-binding protein 43 (TDP-43), and Lewy body
pathology. Using these individual scores, a cumulative
co-pathology burden score was generated for each subject
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(Additional file 1: Table S1). Furthermore, frozen brain tis-
sue (20mg, medial temporal gyrus [MTG]) was obtained
for further biomarker characterization.
Plasma NfL
At the time of assessment, approximately 10mL venous
blood was collected in glass tubes containing sodium ethyl-
enediaminetetraacetic acid (EDTA) from each subject. Par-
ticipants were required to fast for at least 2 h prior to
collection. The blood samples were centrifuged at 2000 x g
at 4 °C for 8min within approximately 2 h of collection.
Plasma supernatant was collected, divided into aliquots,
and frozen at − 80 °C until further use. Plasma NfL concen-
tration was measured using the Simoa platform (NF-light;
Quanterix, Lexington, MA) at the Maurice Wohl Clinical
Neuroscience Institute, London, UK. Samples were ran-
domized, blinded and measured in duplicate using a batch
of reagents from the same lot. The intra-assay and
inter-assay coefficients of variance were 8.1 and 11.2% re-
spectively. The limit of detection (LOD) was 0.52 pg/mL
and the lower limit of quantification (LLOQ) was 3.26 pg/
mL when compensated for a 4-fold sample dilution.
Brain tissue homogenization and biochemical measures
(Aβ1–42, Aβ1–40, P-tau and T-tau)
Frozen post-mortem tissue (20 mg) from the MTG and
subjacent white matter representing Brodmann area 22
(BA22) was obtained for 26 participants with serial
plasma measures. Each sample was homogenized in 10%
(w/v) Tris-buffered saline (TBS + protease inhibitors,
cOmplete™, Roche) and sonicated for 1 min using a son-
icating probe at 4 °C. The tissue lysate underwent
ultra-centrifugation at 100,000 x g for 1 h (4 °C) and the
supernatant was collected (TBS fraction [T]). Two % (w/
v) sodium dodecyl sulfate (SDS) was added to the
remaining pellet that was sonicated further for 1 min at
4 °C and centrifuged at 25,000 g for 1 h (4 °C). The
supernatant was collected as the SDS fraction [S]. Lastly,
70% (w/v) formic acid was added to the remaining pellet,
sonicated and spun under the same conditions as the
SDS fraction. Subsequently, the supernatant was col-
lected and neutralized at 1:20 with 1M Tris for im-
munoassay analysis (formic acid fraction [F]). Tissue
homogenates (T, S and F) were analysed for Aβ1–42,
Aβ1–40, P-tau and T-tau by the human Luminex 4-plex
xMAP assay (Millipore; HNABTMAG-68 K) at the Maur-
ice Wohl Clinical Neuroscience Institute, London, UK.
Briefly, both fractions T and S were diluted 1:2 and frac-
tion F was undiluted (post pH neutralization at 1:20). Me-
dian fluorescent intensity (MFI) was measured using the
Luminex 200 using Xponent 3.1 software. Both raw ab-
sorbance and MFI was exported to Sigma plot (ver13;
Systat software) for estimation of protein concentration
using a five-parameter logistic fit. The intra- and
inter-assay coefficients of variance for Aβ1–40 (8.2% &
16%), Aβ1–42 (6.1% & 16%), P-tau (6.7% & 7%) and T-tau
(9.1% & 14%) respectively. Each individual fraction and
the sum of all fractions were used for further statistical
analysis.
NfL immunohistochemistry & microscopy
Seven μm thick formalin-fixed paraffin-embedded MTG
sections were deparaffinised with xylene and rehydrated
in a graded series of industrial methylated spirit (IMS;
100, 95, 70%). Endogenous peroxidase was quenched
with 0.7% v/v hydrogen peroxide in methanol. Heat-
induced epitope retrieval (HIER) was performed with
citric acid-based antigen unmasking solution (Vector La-
boratories). Sections were blocked with 10% v/v normal
goat serum (Vector Laboratories, S-1000) in Tris-buff-
ered saline (TBS) with 0.25% v/v Triton X-100 (TBS-Tx
0.25%). Mouse anti-NfL chain (clone DA2; 1:200
Table 1 Demographic, clinical (time point 1, 2 & 3) and post-mortem characteristics
CTL AD
Time point 1 2 3 1 2 3
No. 15 12 4 57 57 32
Age, years 86 [79, 87] 88 [83, 90] 90 [89, 95] 83 [77, 88] 84 [78, 89] 87 [79, 89]
Gender, M/F 6/9 7/5 3/1 22/35 22/35 11/21
MMSE 29 [28.5, 30] 29 [28, 30] 29 [28, 29.3] 17 [9, 22] 14 [6, 20] 8 [4, 15]
APOE, ε4 carriers 5/14 (36%) 5/12 (42%) 2/4 (50%) 33/54 (61%) 33/54 (61%) 19/32 (59%)
NfL, pg/mL 29 [23, 34.5] 33 [29.3, 47] 39.3 [33, 45] 42 [33, 57] 48.3 [32, 67] 65 [47.3, 87]
Time to post-mortem, years 7 [3, 8] 7 [4, 8] 6.5 [6, 8] 4 [3, 6] 3 [2, 5] 2 [1, 3]
Braak staging Transentorhinal (I/II) 8 7 3 2 2 0
Limbic (III/IV) 4 3 0 11 11 4
Isocortical (V/VI) 3 2 1 44 44 28
MMSE was found to be lower among CTL subjects, as compared to AD, across all three time points (p < 0.001)
Plasma NfL was higher among AD subjects, relative to controls, at time point 1 (p < 0.01) and at both second and third time points (p < 0.05)
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dilution; Thermo Fisher Scientific, MA1–2010) with 1%
v/v blocking serum in TBS with 0.1% v/v Triton X-100
(TBS-Tx 0.1%) was incubated with sections overnight at
4 °C. Biotinylated goat anti-mouse IgG (1:200 dilution;
Vector Laboratories, BA-9200) in TBS with 0.1% v/v
Tween 20 (TBS-T 0.1%) was applied on the sections for
1 h at RT. Sections were visualised with VECTASTAIN
Elite ABC HRP Kit (Vector Laboratories) and 3,3′-di-
aminobenzidine tetrahydrochloride (DAB) Peroxidase
(HRP) Substrate Kit (Vector Laboratories). Sections were
counterstained in Mayer’s haematoxylin. Sections were
dehydrated in increasing concentrations of IMS (70, 95,
100, 100%) and cleared with xylene. Sections were cover-
slipped with DPX mountant medium. Sections were
scanned using the VS120 Virtual Slide Microscope sys-
tem (Olympus). The density of NfL immunostaining was
measured by the percentage of positive DAB staining
across the entire tissue section using Visiopharm image
analysis program.
Statistical analysis
Levels of plasma NfL between groups were compared
using Wilcoxon signed rank test. Plasma NfL by Braak
stage was examined using one-way ANOVA on ranks,
with post-hoc Wilcoxon signed rank tests where appro-
priate. Categorical variables were compared pairwise
using Fischer’s exact test. Spearman’s rank-order correl-
ation was used to assess the association between plasma
NfL and post-mortem Braak staging, as well as the rela-
tionship between plasma NfL levels and their rate of
change. Linear mixed models, including random inter-
cepts at the subject level, were used to assess longitudinal
changes in NfL levels, with linear models used to assess
the relationship between plasma NfL and MMSE and be-
tween NfL and MTG immunostaining. Given the associ-
ation between NfL and age, all analyses were adjusted for
age at post-mortem as well as for post-mortem delay, the
interval between plasma sampling and death, and
co-pathology burden. Four AD patients were excluded
from our analyses due to outlying plasma NfL values (> 3
standard deviations of the mean). Analyses were per-
formed using R (v.3.3.2, R Foundation for Statistical
Computing, https://www.R-project.org/), with p < 0.05
(two-tailed) used to indicate statistical significance.
Results
Demographic, clinical, and post-mortem Braak staging
characteristics are summarized in Table 1. No significant
Fig. 1 Plasma neurofilament light chain (NfL) concentrations in healthy controls (CTL) versus Alzheimer’s disease (AD) patients at time point 1
(p < 0.001). The horizontal dashes indicate median (long) and quartiles (short)
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between group differences were found for age at base-
line, gender, APOE ε4 carriership, plasma storage time
or in the interval to post-mortem. As expected,
MMSE scores were lower in AD patients, as com-
pared to CTL subjects, at both baseline and longitu-
dinally (p < 0.001). Plasma NfL concentrations were
significantly higher in AD, as compared to CTL sub-
jects, at both time point 1 (p < 0.01, Fig. 1) and sub-
sequent time points (p < 0.05).
Plasma NfL correlates with age and with poorer cognition
independent of age
Across all subjects, plasma concentrations of NfL posi-
tively correlated with age (rho = 0.27, p < 0.05), although
the correlation coefficient was stronger in CTL partici-
pants than AD participants. Due to this effect, a finding
also reported in previous studies (Hansson et al. 2017;
Zetterberg et al. 2016), further statistical analyses were
adjusted for age. As expected, poorer MMSE scores were
associated with increasing post-mortem Braak stages across
all subjects (rho = − 0.61, p < 0.001); among sub-groups,
statistical significance of this correlation held only among
AD subjects (rho = − 0.30, p < 0.05; CTL, rho = − 0.33, p =
0.18). MMSE scores also showed a moderately strong in-
verse correlation with plasma NfL at time point 1 (rho = −
0.49, p < 0.001; Fig. 2). Time point 1 NfL was also associ-
ated with cognitive decline, as evidence by correlations
with MMSE at time points 2 (rho = − 0.46, p < 0.001) and 3
(rho = − 0.31, p < 0.05). These associations, however, were
not significant at the sub-group level.
Plasma NfL is associated with post-mortem Braak staging
Using plasma NfL across all subjects at time point 1, a
moderately strong correlation was observed with post--
mortem Braak stages (rho = 0.55, p < 0.001); further, NfL
levels were found to significantly increase across Braak
stages (isocortical (V/VI) > limbic (III/IV) > transentorh-
inal (I/II); p < 0.001; Fig. 3). Longitudinally, patients with
higher NfL concentration displayed higher Braak staging
at post-mortem (p < 0.001).
Longitudinal increases in plasma NfL
Figure 4 shows median NfL values across time points,
plotted by Braak stage. Using linear mixed modelling,
longitudinal increases in plasma NfL were seen across
all groups (p < 0.01). A significant negative association
was found, however, between plasma NfL at time point
1 and longitudinal measures (NfL rate of change; rho
= − 0.46, p < 0.01) and annual percentage increase
(rho = − 0.42, p < 0.05). No significant differences were
Fig. 2 Time point 1 plasma neurofilament light chain (NfL) concentrations in comparison to global cognition (MMSE; rho = − 0.49, p < 0.001)
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seen between Braak stage group for either of these
longitudinal metrics.
Relationship between plasma NfL and biochemical
measures of Aβ and tau
MTG homogenate measures of Aβ1–40, Aβ1–42, Aβ1–
42/Aβ1–40, P-tau, and T-tau were available for 26 sub-
jects: 7 controls and 19 AD. Firstly, the sum of the
concentrations from fractions T, S and F were exam-
ined. Aβ isoforms, alone (Aβ1–40, Aβ1–42) and in ratio
(Aβ1–42/Aβ1–40) were higher and lower, respectively,
in AD, as compared to controls (p < 0.001; Additional
file 2: Table S2). P-tau was higher in AD, though
T-tau was higher in controls (p < 0.001). Significant
group differences were also seen for separate hom-
ogenate fractions (T, S and F); similar to findings
using the sum of fractions, Aβ and P-tau fractions
were higher in AD, while T-tau fractions were higher
in controls. Among plasma NfL measurements, only
baseline levels significantly associated to the sum of
T-tau fractions (rho = − 0.45, p < 0.05) and its F frac-
tion (rho = − 0.42, p < 0.05).
Inverse relationship between plasma NfL and
immunohistochemical staining of NfL at post-mortem
Formalin-fixed paraffin-embedded MTG sections for 26
participants with longitudinal plasma NfL measures were
immunohistochemically stained for NfL. Percentage of
positive NfL staining (% staining) across the entire tissue
section was measured using Visiopharm image analysis
program. A non-significant trend of decreased % NfL
staining with increased Braak staging was found (rho =
− 0.34, p = 0.102; Fig. 5g). Visualised representation of
decreasing % NfL staining from Braak stage I to VI are
shown in Fig. 5a-f. Further, a significant association be-
tween increased plasma NfL and decreased % NfL stain-
ing was observed (rho = − 0.47, p < 0.01; Fig. 5h). This
was only true for plasma NfL concentrations measured
at time point 3, however (i.e., closest to post-mortem,
median interval 2 years (interquartile range: 1, 3)). No
association was found for plasma NfL at time point 1 or
time point 2.
Discussion
To our knowledge this is the first study investigating
longitudinal measures of plasma NfL in relation to
Fig. 3 Time point 1 plasma neurofilament light chain (NfL) concentrations and Braak staging at post-mortem. The horizontal dashes indicate
median (long) and quartiles (short). Clinical classification was determined at plasma time point 1
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post-mortem measures, including neurofibrillary tangle
(NFT) burden and neurodegeneration as determined by
NfL immunohistochemistry. The main findings demon-
strate that plasma NfL (1) is elevated with increased se-
verity of AD-related NFT pathology at post-mortem, (2)
increases over time independent of tangle pathology at
post-mortem and (3) is inversely associated with the de-
gree of NfL immunostaining at post-mortem. We also
confirm other findings previously reported; plasma NfL
correlates with age (Chatterjee et al. 2018; Gisslen et al.
2016; Lewczuk et al. 2018; Mattsson et al. 2017), how-
ever in our study this is driven by cognitively unimpaired
individuals. Independent of age, plasma NfL correlates
inversely with global cognition (Chatterjee et al. 2018;
Lewczuk et al. 2018; Mattsson et al. 2017) and is increased
in AD, despite large overlaps with other diagnostic groups
(Lewczuk et al. 2018; Mattsson et al. 2017). Together,
these findings support the notion that plasma NfL is a
promising biomarker for neurodegeneration in AD.
There are 4 different neurofilament subunits, includ-
ing NfL, neurofilament medium, neurofilament heavy
and α-internexin. The neurofilaments are critical struc-
tural components of the neural cytoskeleton but their
interaction with mitochondria, microtubules and other
proteins (Yuan et al. 2017) imply their function is far
more imperative than simply axonal stability. In addition
to widespread grey matter loss, substantial white matter
(WM) atrophy is also reported in AD (Delbeuck et al.
2003). These degenerated tracts are composed of
large-caliber myelinated axons that are abundant in neu-
rofilaments (Trojanowski et al. 1986). In previous studies,
CSF measures of NfL have been shown to reflect WM
changes (Sjogren et al. 2001; Zetterberg et al. 2016). Given
the strong correlation of blood and CSF NfL (Disanto et
al. 2017; Gaiottino et al. 2013; Mattsson et al. 2016) maybe
it is unsurprising that we demonstrate blood NfL to reflect
the state of degenerated large-caliber axons at post-mor-
tem. However, this was only observed in plasma measures
at the closest measure to death, and not at the first time
point collection. This may suggest that this is a peripheral
change in advanced dementia. Interestingly, time point 1
plasma NfL (approximately 8 years prior to death) was the
highest in subjects classified as Braak V/VI at post-mor-
tem, despite large group overlaps. We were also able to
demonstrate that individuals classified as Braak III/IV had
higher levels of plasma NfL than Braak I/II. This associ-
ation remained at all subsequent time point plasma collec-
tions. Moreover, our only significant finding with
biochemical brain analysis of core AD biomarkers was an
association was between plasma NfL and P-tau. In support
of these finding, plasma and CSF NfL concentrations have
been shown to correlate with CSF P-tau, the key
Fig. 4 Longitudinal neurofilament light chain (NfL) concentrations by Braak stage. Circles, triangles, and squares indicate median values for
isocortical (Braak V/VI), limbic (Braak III/IV) and transentorhinal (Braak I/II) stages, respectively. Significant increases were seen across all groups,
between time point 1 and subsequent time points (time point 2, p < 0.01; time point 3, p < 0.001)
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component of NFTs, in AD (Mattsson et al. 2017; Zetter-
berg et al. 2016) but not in parkinsonian disorders (Hans-
son et al. 2017). However, it remains unclear if CSF P-tau
truly reflects NFT burden, with mixed findings having been
reported for P-tau181(Buerger et al. 2007; Engelborghs et al.
2007; Seppala et al. 2012), though a positive association has
been reported for P-tau231 (Buerger et al. 2006).
While cross-sectional plasma NfL has been shown to
predict future cognitive decline and correlate with age,
as we have also confirmed, there has been little evidence
to determine how plasma NfL concentrations change
over-time in AD. In this study, longitudinal analysis
from 69 participants demonstrates increases of NfL con-
centration over time, independent of diagnosis and
post-mortem Braak stage stratification. This finding is
likely due to the on-going axonal injury that is associ-
ated with age-related changes. In CSF, NfL normal refer-
ence ranges increase 2.5-fold between 20 years and 50
years, doubling by the age of 70 years (Yilmaz et al.
2017). Furthermore, studies in healthy ageing indicate
that CSF NfL remains a predictor of hippocampal atro-
phy that is independent of age and other AD biomarkers
(Idland et al. 2017). In this current study, negative asso-
ciations were found between time point 1 plasma NfL
concentrations in both its rate of change and annual per-
centage increase. One might expect a slower trajectory
of NfL after initial increases in groups with more severe
pathology (in this study, likely to be AD) at post-mortem,
as this may well reflect a deceleration in neurodegenera-
tion. Longitudinal decreases in CSF tau have also been
Fig. 5 Formalin-fixed paraffin-embedded MTG sections stained for mouse anti-neurofilament light chain (clone DA2), one representative section from
each Braak stage (I-VI) is displayed (a-f). The relationship between % NfL staining in the MTG and Braak staging at post-mortem (rho =− 0.34, p= 0.102) (g).
A significant negative correlation between plasma NfL time point closest to death and % NfL staining in the MTG at post-mortem (rho =− 0.47, p< 0.01 (h)
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reported, possibly indicating a deceleration in neurode-
generation due to substantial neuronal loss (Sutphen et
al. 2018). This hypothesis has also gained support from
recent stable isotope labelling kinetics (SILK) studies
that track the turnover of tau in the human CNS (Sato
et al. 2018). However, in this study, a slowed trajectory
of plasma NfL was observed in all groups (including
Braak I/II and controls) and therefore the reported
aged-related reduction in CSF turnover (Reiber 1994)
may be a better explanation of this finding.
In the clinical work-up of suspected neurodegenerative
disease, NfL will most likely be of limited value from a
differential diagnostic perspective (with the differenti-
ation of typical idiopathic Parkinson's disease from atyp-
ical parkinsonian disorders being one potential
exception (Hansson et al. 2017)) but could instead be
used to determine disease intensity, predict progression
or rule out on-going neurodegeneration for cognitive
complaints. Our data also suggests that plasma NfL
could provide prognostic information as to the extent
of NFT involvement in disease progression, which
might prove important if immunotherapies targeting
pathological tau in AD become available. However,
the most promising application of plasma NfL is in
evaluating treatment response in AD, as seen in mul-
tiple sclerosis studies (Novakova et al. 2017), as re-
cent animal studies using β-secretase inhibitors have
shown reduction in plasma NfL (Bacioglu et al. 2016).
This study is not without limitations. Although the
primary aim was to associate plasma NfL with post-mor-
tem pathology, conclusions about plasma NfL in isola-
tion are based upon a smaller sample size than previous
investigations. Further, given the nature of the study and
cohort, cross-sectional, longitudinal and post-mortem
participants had a bias toward AD participants com-
pared to aged controls. AD patients were elderly, with a
majority showing severe dementia, particularly at later
time points. As such, our observations surrounding NfL
are confined to a late portion of the AD continuum, one
potentially also confounded by brain pathologies other
than amyloid-β and tau (e.g., α-synuclein, TDP-43 and
vascular lesions) (James et al. 2016), which have been
shown to increase in prevalence with age (Schneider et
al. 2007) and involve brain regions not examined in this
study. Though we attempted to control for this by
adjusting our analyses for a cumulative measure of re-
ported co-pathology, this included only selected patholo-
gies. In addition, while a useful measure of global
cognition, the MMSE was designed to measure cognitive
deficits in patients in the mild-to-moderate stages of de-
mentia, and has been found to be deficient in detecting
more severe cognitive decline, tending to show floor ef-
fects in patients with profound dementia (Herrmann et
al. 2007; Vellas et al. 2005).
Conclusion
This study, for the first time, demonstrates that plasma
NfL is not only reflective of CSF biomarker changes but
also of NFT pathology and neurodegeneration (as deter-
mined by NfL) at post-mortem. This important finding
adds further, yet unique, support to the use of plasma NfL
as a simple, accessible screening tool to rule out on-going
neurodegeneration in primary care and for population en-
richment and response monitoring in clinical trials.
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